Therapeutic Conyergence: AI, CRISPR, and Pharmacogenomics for Mutation-Centric Medicine

The intersection of AI, CRISPR-Cas9, NGS and pharmacogenomics This combination is changing the face
of biomedical research and precision medicine. AI supports improved gRNA design, ofi-target cffects prediction and identification of novel CRISPR enzymes for safer genetic therapies which better address individuals. In oncology, NGS is used for high-resolution tumor mutation profiles and liquid biopsy monitoring and CRISPR/Cas9 also offers a way to precisely edit mutations (e.g, improve immunotherapy such as CAR-T cells or target resistance). Emerging CRISPR tools, like prime editing, base editing, and
CRISPRon improve the targcting accuracy and specificity. Pharmacogenomics brings forward the prospect
of individualizing drug therapy through such drugs and treatments that will have optimum safety and eficacy. It speeds identification of biomarkers and prediction of drug response in oncology, neurology, and metabolic disease. Both allow treatment to be tailored on a patient-treatment specific level and both
enable mutation-focused therapy. However, ethical, regulatory and data privacy issues persist. The use of the technology in socicty requires support from experts and stakeholders to ensure equal.
Keywords: Artificial Intelligence (AD), CRISPR-Cas9, Next-Generation Seguencing (NGS)
Pharmacogenomics, Precision Medicine